

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



May 27, 2023

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051,
Maharashtra, India.

BSE Limited
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai – 400 001, Maharashtra, India.

NSE Code: SUNPHARMA

BSE Code: 524715

Dear Sir/ Madam,

Subject - Appointment of Directors

The Board of Directors at their meeting held on May 26, 2023, inter alia, have approved the following:

1. Appointment of Mr. Rolf Hoffmann as an Independent Director

Mr. Rolf Hoffmann has been appointed as Independent Director for a term of five years to be effective from the date of allotment of Director Identification Number.

Brief profile of Mr. Rolf Hoffmann is enclosed as **Annexure A**. Mr. Hoffmann is not related to any Director of the Company. Further, Mr. Hoffmann, is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India (SEBI) or any other such authority.

2. Appointment of Mr. Aalok Shanghvi as a Whole-time Director

Mr. Aalok Shanghvi (DIN: 01951829) has been appointed as a Whole-time Director, for a term of five years effective from June 1, 2023.

Brief profile of Mr. Aalok Shanghvi is enclosed as **Annexure B**. Mr. Aalok Shanghvi is the son of Mr. Dilip Shanghvi, Managing Director and Promoter of the Company and is nephew of Mr. Sudhir Valia, Non-Executive Director of the Company. Mr. Aalok Shanghvi, is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India (SEBI) or any other such authority.

The appointments mentioned above are subject to approval by the shareholders pursuant to Regulation 17(1C) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and dissemination.

Thank You.

For Sun Pharmaceutical Industries Limited

(Anoop Deshpande)
Company Secretary & Compliance Officer
ICSI Membership No.: A23983

Mr. Rolf Hoffmann



Mr. Rolf Hoffmann is a Strategic and results-orientated Executive who is highly respected for expertise in creating and optimizing commercial opportunities in all global markets. He has over 29 years of experience managing top 50 worldwide markets with full P&L and cross-functional accountability.

Mr. Hoffmann has worked with Eli Lilly and Company for over a 17-year period with a balance of in-country management, international regional management and headquarters global executive positions. In his various responsibilities, he established a regulatory and governmental affairs network around the world, developed in-depth commercial capabilities for all geographies including alliances, joint venture, and organic growth strategy. Mr. Hoffmann was a highly respected operational leader and presenter with continued upward momentum when recruited by Amgen, where he spent about 12-years at various leadership roles and responsibilities, including P&L accountabilities for all countries around the world including the USA.

Mr. Hoffmann has served on various board viz., Ferring Holding Inc., New Jersey, USA, Trizell Holding S.A., Lausanne, Switzerland, Shield Therapeutics PLC, Gateshead Quays, UK, EUSA Pharma, Hemel Hempstead, UK, Biotest AG, Dreieich, Germany, Trigemina, Inc., San Francisco, USA and STADA AG, Bad Vilbel, Germany. He currently serves the board of Genmab A/S, Copenhagen, Denmark, Paratek Pharmaceuticals, Inc., Boston, USA, Sendor Pharma Group GmbH, Cologne, Germany and IDT Biologika GmbH, Dessau-Rosslau, Germany.

Mr. Hoffmann has received an *MBA*, Kenan-Flagler Business School, UNC Chapel Hill, North Carolina, 1987, *MA - English*, The University of Koeln, Koeln, Germany, 1985 and *MA - Kinesiology*, Deutsche Sporthochschule Koeln, Koeln, Germany, 1985.

Annexure B

Mr. Aalok Shanghvi

Executive Vice-President, Head - Emerging Markets, Global Generic R&D, Global Generic Business Development & API



Aalok joined Sun in 2006 and has handled various roles in Marketing, R&D, Project Management, Purchase & Communications. In 2010, he headed Bangladesh and by 2014, he took over the Emerging Markets business, which is spread across 80 countries covering Africa, Middle East, APAC, Eastern Europe, CIS, and Latam. Subsequently, he also took charge of Global Generic R&D, Global Generic Business Development and API. He has done his undergraduate majoring in Cellular and Molecular Biology from the University of Michigan – Ann Arbor.